Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

CABA Insider Trading

Cabaletta Bio, Inc. | Biological Products, (No Diagnostic Substances)

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Cabaletta Bio, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Biological Products, (No Diagnostic Substances) sector.

Last 7 Days
$0
Buys
$0
Sells
Last 30 Days Trend
$296,189
Buys
$0
Sells

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2026-01-22 02:56 2026-01-21 Chang David J. Officer - Chief Medical Officer BUY $2.26 8,800 $19,888 8,800 +100.0%
2026-01-22 02:56 2026-01-21 Binder Gwendolyn Officer - President, Science & Tech. BUY $2.19 11,312 $24,763 31,312 +56.6%
2026-01-22 02:55 2026-01-21 Tomasello Shawn Director BUY $2.21 22,725 $50,322 22,725 +100.0%
2026-01-22 02:55 2026-01-21 Gavel Steve Officer - Chief Commercial Officer BUY $2.27 22,170 $50,215 22,170 +100.0%
2026-01-22 02:54 2026-01-21 Bollard Catherine Director BUY $2.27 4,405 $9,982 5,405 +440.5%
2026-01-22 02:54 2026-01-21 Nichtberger Steven Director, Officer - President & CEO BUY $2.24 45,000 $100,778 1,031,483 +4.6%
2026-01-22 02:53 2026-01-21 Simon Mark Director BUY $2.28 11,061 $25,261 147,205 +8.1%
2026-01-22 02:53 2026-01-21 Gerard Michael Officer - General Counsel BUY $2.27 6,600 $14,979 6,600 +100.0%
2024-01-20 02:30 2024-01-19 Binder Gwendolyn Officer - See Remarks OPT+S $19.59 11,000 $215,439 20,000 0.0%
2023-12-20 04:37 2023-12-19 Binder Gwendolyn Officer - See Remarks OPT+S $21.89 11,000 $240,789 20,000 0.0%
2023-11-22 00:30 2023-11-20 Binder Gwendolyn Officer - See Remarks OPT+S $17.82 11,000 $196,013 20,000 0.0%
2023-10-20 02:40 2023-10-19 Binder Gwendolyn Officer - See Remarks OPT+S $13.36 11,000 $146,920 20,000 0.0%
2023-09-20 23:30 2023-09-19 Binder Gwendolyn Officer - See Remarks OPT+S $17.57 11,000 $193,219 20,000 0.0%
2023-08-22 23:30 2023-08-21 Binder Gwendolyn Officer - See Remarks OPT+S $13.42 11,000 $147,583 20,000 0.0%
2023-07-20 03:37 2023-07-19 Binder Gwendolyn Officer - See Remarks OPT+S $13.82 11,000 $152,022 20,000 0.0%
2023-06-21 23:38 2023-06-20 Binder Gwendolyn Officer - See Remarks OPT+S $12.99 11,000 $142,925 20,000 0.0%
2023-05-20 03:10 2023-05-19 Binder Gwendolyn Officer - See Remarks OPT+S $11.81 22,000 $259,833 20,000 0.0%
2022-10-20 03:19 2022-10-19 Nichtberger Steven Director, Officer - President & CEO BUY $1.25 8,127 $10,152 986,483 +0.8%
2022-10-19 04:51 2022-10-18 Bollard Catherine Director BUY $0.99 1,000 $994 1,000 +100.0%
2022-10-19 04:50 2022-10-18 Marda Anup Officer - Chief Financial Officer BUY $0.99 50,000 $49,620 50,000 +100.0%
2022-10-19 04:50 2022-10-18 Simon Mark Director BUY $0.98 125,000 $122,125 7,000 +100.0%
2022-10-19 04:50 2022-10-18 Binder Gwendolyn Officer - See Remarks BUY $0.99 20,000 $19,894 20,000 +100.0%
2022-10-19 04:50 2022-10-18 Nichtberger Steven Director, Officer - President & CEO BUY $0.99 141,873 $141,008 978,356 +17.0%
2021-11-03 23:38 2021-11-01 5AM Ventures V, L.P. 10% owner SELL $13.00 295,000 $3,835,000 333,144 -47.0%
2021-09-10 00:34 2021-09-07 5AM Ventures V, L.P. 10% owner SELL $9.70 625,000 $6,062,500 1,989,575 -23.9%
2021-01-13 01:07 2021-01-08 5AM Ventures V, L.P. 10% owner SELL $13.00 387,000 $5,031,000 369,688 -51.1%
2020-12-15 01:58 2020-12-10 5AM Ventures V, L.P. 10% owner SELL $14.75 298,000 $4,395,500 417,629 -41.6%
2019-11-01 01:03 2019-10-29 5AM Ventures V, L.P. 10% owner BUY $11.00 454,545 $4,999,995 454,545 +100.0%
2019-10-31 01:04 2019-10-29 Flynn James E 10% owner, Other BUY $11.00 700,000 $7,700,000 700,000 +100.0%
SHOW ENTRIES
1-29 OF 29

How to Interpret $CABA Trades

Not every insider transaction in Cabaletta Bio, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $CABA shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for CABA

Insider activity data for Cabaletta Bio, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $CABA, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.